The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
Abstract Objective To compare the efficacy and safety of first‐line anti‐PD‐1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method Patients with advanced UC who received first‐line treatment of chemotherapy (n = 51, gemcitabine/paclitaxel [...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6671 |
| _version_ | 1797387140484562944 |
|---|---|
| author | Fuxin Han Zhaozhen Wu Jiaxin Chen Meicen Liu Yi Hu |
| author_facet | Fuxin Han Zhaozhen Wu Jiaxin Chen Meicen Liu Yi Hu |
| author_sort | Fuxin Han |
| collection | DOAJ |
| description | Abstract Objective To compare the efficacy and safety of first‐line anti‐PD‐1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method Patients with advanced UC who received first‐line treatment of chemotherapy (n = 51, gemcitabine/paclitaxel [albumin‐bound] combined with platinum) or immunochemotherapy (n = 50, PD‐1 inhibitors plus chemotherapy) were enrolled. The efficacy and safety were analyzed between the two groups. Results This study included data from 101 patients, including 51 patients in the chemotherapy group and 50 patients in the immunochemotherapy group. The median progression‐free survival of the immunochemotherapy group was significantly longer than that of the chemotherapy group (11.5 vs. 7.17 m, HR = 0.56, p = 0.009). The two groups' overall survival showed no significant difference (20.3 vs. 17.8 m, p = 0.204). The objective response rates and the disease control rates of the two groups were 38.0% versus 49.0% (p = 0.26) and 88.0% versus 80.4% (p = 0.29). The incidence of adverse reactions (AEs) in the immunochemotherapy group and chemotherapy group were 90.0% and 84.3% (p = 0.394), respectively, and the incidence of Grade III–IV AEs were 32.0% and 35.3% (p = 0.726), respectively. Conclusion In the first‐line treatment of patients with advanced UC, anti‐PD‐1 therapy combined with chemotherapy might have better efficacy than chemotherapy alone, and AEs are similar between the two groups. |
| first_indexed | 2024-03-08T22:19:36Z |
| format | Article |
| id | doaj.art-b204fcbf308445d2a14ed845c0759cb8 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T22:19:36Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-b204fcbf308445d2a14ed845c0759cb82023-12-18T14:43:07ZengWileyCancer Medicine2045-76342023-12-011223211292113710.1002/cam4.6671The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinomaFuxin Han0Zhaozhen Wu1Jiaxin Chen2Meicen Liu3Yi Hu4Medical School of Chinese PLA Beijing ChinaBeijing Chest Hospital Capital Medical University Beijing ChinaDepartment of Genetic Engineering Beijing Institute of Biotechnology Beijing ChinaSchool of Medicine Nankai University Tianjin ChinaDepartment of Oncology The First Medical Centre Chinese PLA General Hospital Beijing ChinaAbstract Objective To compare the efficacy and safety of first‐line anti‐PD‐1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method Patients with advanced UC who received first‐line treatment of chemotherapy (n = 51, gemcitabine/paclitaxel [albumin‐bound] combined with platinum) or immunochemotherapy (n = 50, PD‐1 inhibitors plus chemotherapy) were enrolled. The efficacy and safety were analyzed between the two groups. Results This study included data from 101 patients, including 51 patients in the chemotherapy group and 50 patients in the immunochemotherapy group. The median progression‐free survival of the immunochemotherapy group was significantly longer than that of the chemotherapy group (11.5 vs. 7.17 m, HR = 0.56, p = 0.009). The two groups' overall survival showed no significant difference (20.3 vs. 17.8 m, p = 0.204). The objective response rates and the disease control rates of the two groups were 38.0% versus 49.0% (p = 0.26) and 88.0% versus 80.4% (p = 0.29). The incidence of adverse reactions (AEs) in the immunochemotherapy group and chemotherapy group were 90.0% and 84.3% (p = 0.394), respectively, and the incidence of Grade III–IV AEs were 32.0% and 35.3% (p = 0.726), respectively. Conclusion In the first‐line treatment of patients with advanced UC, anti‐PD‐1 therapy combined with chemotherapy might have better efficacy than chemotherapy alone, and AEs are similar between the two groups.https://doi.org/10.1002/cam4.6671adverse reactionschemotherapyefficacyPD‐1 inhibitorsurothelial carcinoma |
| spellingShingle | Fuxin Han Zhaozhen Wu Jiaxin Chen Meicen Liu Yi Hu The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma Cancer Medicine adverse reactions chemotherapy efficacy PD‐1 inhibitors urothelial carcinoma |
| title | The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma |
| title_full | The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma |
| title_fullStr | The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma |
| title_full_unstemmed | The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma |
| title_short | The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma |
| title_sort | efficacy and safety of chemotherapy with or without anti pd 1 for the first line treatment of advanced urothelial carcinoma |
| topic | adverse reactions chemotherapy efficacy PD‐1 inhibitors urothelial carcinoma |
| url | https://doi.org/10.1002/cam4.6671 |
| work_keys_str_mv | AT fuxinhan theefficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT zhaozhenwu theefficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT jiaxinchen theefficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT meicenliu theefficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT yihu theefficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT fuxinhan efficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT zhaozhenwu efficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT jiaxinchen efficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT meicenliu efficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma AT yihu efficacyandsafetyofchemotherapywithorwithoutantipd1forthefirstlinetreatmentofadvancedurothelialcarcinoma |